Kestra Medical Technologies, Ltd.
NASDAQ:KMTSMedical - Instruments & Supplies
-$0.07 today
- Market cap
- $1.69B
- Beta
- 0.83
- P/E (TTM)
- -6.9
- EPS (TTM)
- -$2.74
Volume 0.44M
Average 0.33M
KMTS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Kestra Medical Technologies, Ltd.NASDAQ: KMTS
Net Income · Q3 FY2026 · quarter ended Jan 2026
Net income grows, but more slowly than its trailing trend
Q3 FY2026 net income of $34.17M (cash outflow) rose 57.0% year over year, behind the +69.3% change in trailing-twelve-month net income. Sequentially, it rose 4.2% from the prior quarter.
Context
- Net income amounted to 190.3% of revenue in FY2025, down 148.1 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$136.55M (+20.0%) for the fiscal year ending Apr 2026, a pace similar to FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJan 2026
- -$34.17M+4.2% QoQ
- Last fiscal yearApr 2025
- -$113.81M+20.9% YoY
- LTMJan 2026
- -$143.89M+69.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +57.0% | -32.4% | -89.4 pp |
| 1 year | +20.9% | +20.0% | -0.9 pp |
| 3-year CAGR | — | +2.5% | — |
| 5-year CAGR | -10.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (113.81M) USD
- Year-over-year change
- -20.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | (113.81M) | -20.9% |
| FY2024 | 2024-04-30 | (94.12M) | -11.7% |
| FY2023 | 2023-04-30 | (84.24M) | — |
| FY2021 | 2021-04-30 | (34.1M) | -15.7% |
| FY2020 | 2020-04-30 | (29.47M) | — |
Net Income vs competitors
How KMTS compares with its peers on the latest reported figures
- KMTS's LTM Jan 2026 net income of $143.89M is the largest of the 3 companies compared; the peer median is $45.62M.
- Its year-over-year change of +69.3% is the highest of 3, against a peer median of -11.4%.
- Net income amounts to 171.9% of revenue for KMTS, versus a peer median of 46.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jan 2026 | $143.89M | +69.3% | — | 171.9% | |
| LTM Mar 2026 | $52.66M | +2.2% | +8.8% | 89.1% | |
| LTM Sep 2026 | $38.59M | -25.0% | -27.3% | 4.5% | |
| Peer median (excluding KMTS) | $45.62M | -11.4% | -9.3% | 46.8% | |
Competitors are the stored peer set for KMTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Apr 2020 | FY2021 Apr 2021 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Net Income | (29.47M) | (34.1M) | (84.24M) | (94.12M) | (113.81M) |
| Depreciation & Amortization | 478K | 420K | 4.86M | 11.56M | 7.97M |
| Deferred Income Tax | 0 | 0 | (45K) | 12K | 64K |
| Stock-Based Compensation | 0 | 1.86M | 1.21M | 1.49M | 24.27M |
| Change in Working Capital | (2.01M) | (19K) | 1.3M | 4.39M | (6.2M) |
| Accounts Receivables | 0 | 0 | 0 | (2M) | (8.78M) |
| Inventory | 0 | 0 | (733K) | (1.18M) | (3.44M) |
| Accounts Payables | (790K) | (132K) | 2.14M | 7.34M | 2.84M |
| Other Working Capital | (1.22M) | 113K | (112K) | 223K | 3.18M |
| Other Non-Cash Items | 706K | 1.94M | 7.28M | 4.44M | 10.11M |
| Operating Cash Flow | (30.29M) | (29.9M) | (69.64M) | (72.24M) | (77.61M) |
| Capital Expenditures | (232K) | (336K) | (15.46M) | (12.51M) | (23.59M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 2K | 0 | 285K | 283K |
| Investing Cash Flow | (232K) | (334K) | (15.46M) | (12.23M) | (23.31M) |
| Debt Repayment | 0 | 20M | (5.33M) | 5.88M | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 215.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (183K) | (187K) | (671K) | (799K) | (1.65M) |
| Other Financing Activities | 30.42M | 29M | 0 | (2.35M) | 12.73M |
| Financing Cash Flow | 30.24M | 48.82M | 96.11M | 77.73M | 330.26M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (286K) | 18.59M | 11M | (6.74M) | 229.35M |
| Free Cash Flow | (30.53M) | (30.23M) | (85.1M) | (84.75M) | (101.2M) |
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
Intrinsic Alpha fair value
Locked
Current Price
$28.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.